# Selank Research: Mechanism, Studies & the Evidence Base > Selank research summarized — the GABAergic and enkephalinase mechanisms, the BDNF and immune findings, and the key rodent and clinical studies, all cited. The two core mechanisms, the neurotrophic and immune findings, and an honest read of the evidence base. ## The gist Selank research splits into two main stories. The first is GABA — the brain's main calming chemical. Studies say Selank gently boosts how GABA receptors respond and shifts the activity of GABA-related genes, which lines up with its anti-anxiety effect. The second is the body's own opioid system: Selank slows down enzymes that destroy enkephalins, the natural molecules that ease stress and pain, so more of them stay around longer. On top of that, it raises a brain-growth protein called BDNF in rats, changes serotonin and dopamine activity, and tweaks immune signaling because it comes from tuftsin, an immune peptide. Most of this is rat data plus a handful of Russian clinical studies. The science is consistent and interesting, but thin by Western standards — so the studies below are described carefully, not oversold. ## Mechanism: the GABAergic system Selank's anxiolytic activity centers on GABA, the central nervous system's principal inhibitory neurotransmitter. A binding-data review characterizes Selank as a positive allosteric modulator of [3H]GABA binding — it enhances the receptor's response from a site distinct from where GABA itself binds — and notes it can block the modulatory activity of diazepam and olanzapine, pointing to distinct but overlapping binding sites [1]. The gene-expression evidence reinforces this. A single 300 µg/kg dose in rat frontal cortex significantly changed the expression of 45 genes at one hour and 22 genes at three hours, and the direction of those shifts correlated positively with the changes GABA produces on its own [4]. In a human neuroblastoma cell line (IMR-32), Selank again altered the expression of GABA-pathway genes, with a signature partly overlapping GABA's [11]. Together these results describe a GABAergic mechanism that is real but distinct from how benzodiazepines act. ## Mechanism: enkephalinase inhibition and the opioid system The second mechanism runs through endogenous opioids. In human plasma in vitro, Selank dose-dependently inhibited enkephalin-degrading enzymes with an IC50 of approximately 15 µM — slowing the breakdown of enkephalins, the body's own anti-anxiety peptides, and proposed to normalize the shortened enkephalin half-life seen in generalized anxiety [2]. Both Selank and Semax share this peptidase-inhibition property in human serum, a trait common to tuftsin- and ACTH-derived regulatory peptides [8]. The behavioral evidence ties this directly to anxiety. In rats, Selank's "depriming" effect on apomorphine-induced behavior was abolished by naloxone, an opioid-receptor blocker — implicating the opioid system in its anti-anxiety action [9]. Across mouse strains with different emotionality, the contribution of the opioid system to Selank's effect varied by phenotype [10], and in mice it modified anxiety-related behavior while reducing plasma enkephalin-degrading enzyme activity in a strain-dependent way [20]. ## Neurotrophic and monoaminergic findings Beyond calming, Selank touches the machinery of neuroplasticity. After intranasal administration, it regulated (increased) BDNF expression in the rat hippocampus in vivo — linking the peptide to neurotrophic signaling and offering a mechanistic basis for its nootropic-like effects in learning tasks [3]. It also shifts monoamines. In BALB/c and C57Bl/6 mice, the heptapeptide altered the content of serotonin and dopamine and their metabolites in a strain-dependent manner [17], and in rats it was used to correct measures of integrative brain activity and biogenic amine levels [12]. These monoaminergic effects sit alongside the GABA and opioid mechanisms rather than replacing them. ## Immune and physiological signals Because Selank derives from tuftsin (an immunomodulatory fragment of immunoglobulin G), it carries immune activity uncommon among anxiolytics. In patients with anxiety-asthenic disorders it altered the Th1/Th2 cytokine balance and modulated peripheral-blood IL-6, leading the authors to describe it as a novel immunomodulator [6]. In rats under stress it influenced cytokine levels [18], and in mice it showed antiviral activity in experimental influenza infection, consistent with its tuftsin-derived lineage [19]. The physiological record extends to the gut. Selank increased gastric wall blood flow and supported mucosal defense in rats [14], and Selank with its metabolites preserved gastric mucosal homeostasis under challenge [15]. It also modulated hepatocyte functional indices under immobilization stress, studied as part of its broader physiology profile [16]. ## Selank peptide and N-Acetyl Selank The base Selank peptide is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, and it is the form used in essentially all of the cited research above. A separate variant, **N-Acetyl Selank** (often called Selank Amidate in research-chemical listings), is an N-terminally acetylated modification marketed with claims of greater stability or potency. It is important to be precise here: the published, citable Selank literature — the GABA gene-expression work, the enkephalinase IC50, the BDNF and clinical findings — was conducted on the base heptapeptide [1][2][3][4]. The acetylated variant does not have its own comparable body of peer-reviewed evidence, so claims specific to it should be read with caution and not treated as carrying the base peptide's research record. ## Reading the evidence honestly The strengths and limits of the Selank record both deserve naming. The mechanisms are coherent and reproduced across several rodent and in vitro models, and a small set of clinical studies report a genuine anxiolytic effect without sedation or dependence [5]. But the great majority of studies originate from a small number of Russian research groups, many in Russian-language journals with English abstracts only, and independent Western replication is limited. Human pharmacokinetics of intact Selank are poorly characterized in mainstream literature, and the human evidence is far thinner than for approved anxiolytics. None of this negates the findings — it sets the confidence level. This is a coherent single-region research program, not a globally validated drug. --- An independent, plainly-written digest of the Selank research — the GABA and enkephalinase findings reported as the studies measured them, the single-region evidence base and unknown human pharmacokinetics named without flinching, and community impressions kept on their own side as anecdote; no clinic, no vendor, and nothing here prescribed.